Hope for young women born without a vagina: Scientists successfully implant organs grown in the lab using patients' own cells
- The new organs given to women born with a condition called MRKH
- This is rare condition in which the vagina is underdeveloped or absent
- Treatment could also help patients with vaginal cancer or injuries
- Organ is engineered using muscle and cells from the genital region
Scientists have successfully grown vaginas in a laboratory and implanted them into four teenage patients. The
new organs have been given to women born with MRKH -
Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, a rare genetic condition
in which the vagina and uterus are underdeveloped or absent. The
treatment could also potentially be applied to patients with vaginal
cancer or injuries, according to the U.S. researchers.
HOW THEY DID IT
The
organ structures were engineered using muscle and epithelial cells (the
cells that line the body’s cavities) from a small biopsy of each
patient’s external genitals. The cells were extracted from the tissues, expanded and then placed on a
biodegradable material that was hand-sewn into a vagina-like shape. These scaffolds (pictued below) were tailor-made to fit each patient.
About five to six weeks after the biopsy, surgeons created a canal in the patient’s pelvis and attached the scaffold to reproductive structures.
About five to six weeks after the biopsy, surgeons created a canal in the patient’s pelvis and attached the scaffold to reproductive structures.
At
the same time the scaffolding material is being absorbed by the body,
the cells lay down materials to form a permanent support structure –
gradually replacing the engineered scaffold with a new organ. The researchers, from the Wake Forest
Baptist Medical Center's Institute for Regenerative Medicine, say four
teenage girls have successfully received vaginal organs that were
engineered with their own cells.Writing
in The Lancet, programme leader by Dr Anthony Atala, said: 'This pilot
study is the first to demonstrate that vaginal organs can be constructed
in the lab and used successfully in humans.
'This may represent a new
option for patients who require vaginal reconstructive surgeries. In
addition, this study is one more example of how regenerative medicine
strategies can be applied to a variety of tissues and organs.' The
girls were between 13 and 18 years old at the time of the surgeries,
which were performed between June 2005 and October 2008. Data from annual follow-up visits show that even up to eight years after the surgeries, the organs had normal function. The vaginas were engineered using muscle and epithelial
cells (the cells that line the body's cavities) from a small biopsy of
each patient's external genitals. The cells were then extracted from the tissues, expanded and then
placed on a biodegradable material that was hand-sewn into a vagina-like
shape. These scaffolds were tailor-made to fit each patient.
About
five to six weeks after the biopsy, surgeons created a canal in the
patient's pelvis and sutured the scaffold to reproductive structures. Previous research in Dr Atala's lab has shown that
once cell-seeded scaffolds are implanted in the body, nerves and blood
vessels form and the cells expand and form tissue. At the same time the
scaffolding material is being absorbed by the body, the cells lay down
materials to form a permanent support structure – gradually replacing
the engineered scaffold with a new organ. Follow-up testing on the
lab-engineered vaginas showed the margin between native tissue and the
engineered segments was indistinguishable. In addition, the patients' responses to a Female Sexual Function
Index questionnaire showed they had normal sexual function after the
treatment, including desire and pain-free intercourse.
"Tissue
biopsies, MRI scans and internal exams using magnification all showed
that the engineered vaginas were similar in makeup and function to
native tissue, said Atlantida-Raya Rivera, lead author and director of
the HIMFG Tissue Engineering Laboratory in Mexico City, where the
surgeries were performed. Current
treatments for MRHK syndrome include dilation of existing tissue or
reconstructive surgery to create new vaginal tissue. A
variety of materials can be used to surgically construct a new vagina –
from skin grafts to tissue that lines the abdominal cavity. However,
these substitutes often lack a normal muscle layer and some patients can
develop a narrowing or contracting of the vagina. The
researchers say that with conventional treatments, the overall
complication rate is as high as 75 percent in paediatric patients, with
the need for vaginal dilation due to narrowing being the most common
complication.
WHAT IS MRKH SYNDROME?
- MRKH (Mayer Rokitansky Küster Hauser) is a congenital abnormality which affects one in 5,000 women in the UK.
- It is characterised by the absence of the vagina, womb and cervix.
- Women suffering from the condition will have normally functioning ovaries and so will experience the normal signs of puberty but will not have periods or be able to conceive.
- The external genatalia are completely normal which is why MRKH isn’t usually discovered until women are in their teenage years.
- It’s usually discovered when the woman tries to has sex or fails to get her period.
- Many women are able to create a vaginal canal using dilation treatment, which uses cylinder shaped dilators of different sizes to stretch the muscles.
- However, if this is unsuccessful then surgery will be used to stretch the vaginal canal.
- Following treatment women are able to have intercourse and can have their eggs removed and fertilised to be used in surrogacy.
No comments:
Post a Comment